Evidence map›Paper›PMID 36460700›Full record

ArticleScientific reports2022

Ozone modified hypothalamic signaling enhancing thermogenesis in the TDP-43

Sara Rodríguez-Sánchez, Nicolas Valiente, Susana Seseña, Marta Cabrera-Pinto, Ana Rodríguez, Alfonso Aranda, Llanos Palop, Carmen M Fernández-Martos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Sara Rodríguez-SánchezFaculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Toledo, Spain.
Nicolas Valiente *Division of Terrestrial Ecosystem Research, Centre for Microbiology and Environmental Systems Science, University of Vienna, Vienna, Austria.
Susana Seseña *Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Toledo, Spain.
Marta Cabrera-PintoHospital Nacional de Parapléjicos, SESCAM, Toledo, Spain.
Ana RodríguezFaculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Toledo, Spain.
Alfonso ArandaFaculty of Chemical Science and Technology, University of Castilla-La Mancha, Ciudad Real, Spain.
Llanos PalopFaculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Toledo, Spain.
Carmen M Fernández-MartosHospital Nacional de Parapléjicos, SESCAM, Toledo, Spain. cmfernandezm@sescam.jccm.es.
University of Castilla-La Mancha · ESHospital Nacional de Parapléjicos · ESUniversity of Tasmania · AUUniversity of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS), a devastating progressive neurodegenerative disease, has no effective treatment. Recent evidence supports a strong metabolic component in ALS pathogenesis. Indeed, metabolic abnormalities in ALS correlate to disease susceptibility and progression, raising additional therapeutic targets against ALS. Ozone (O

Indexed as

Amyotrophic Lateral SclerosisNeurodegenerative DiseasesOzoneAnimalsDNA-Binding ProteinsHypothalamusMiceThermogenesisDNA-Binding ProteinsOzoneTardbp protein, mouse

Identifiers

PMID36460700
PMCPMC9718766
OpenAlexW4311191873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.